Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece

References

• NestleFOKaplanDHBarkerJPsoriasisNEJM2009361549650919641206
   PubMed Web of Science ®Google Scholar
• MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res2011303111020857129
   PubMed Web of Science ®Google Scholar
• World Health OrganizationThe known health effects of UV [webpage on the Internet] Available at: http://www.who.int/uv/faq/uvhealtfac/en/index1.htmlAccessed November 13, 2014
   Google Scholar
• EnamandramMKimballABPsoriasis epidemiology: the interplay of genes and the environmentJ Invest Dermatol2013133228728923318785
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• BassukasIDMavridouKAEvangelouTGaitanisGThe prevalence of psoriasis among elderly individuals: more questions than answers [webpage on the Internet]Ageing Res201121 Available at: http://www.pagepress.org/journals/index.php/ar/article/view/ar.2011.e1/html_93Accessed November 13, 2014
   Google Scholar
• RigopoulosDGregoriouSKatrinakiACharacteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climateEur J Dermatol201020218919520123642
   PubMed Web of Science ®Google Scholar
• SamoutisAKaitelidouDSiskouOModerate and severe plaque psoriasis: a quality of life and cost-of-illness study from GreeceIntl J Caring Sci201252
   Google Scholar
• KyriakisKPPalamarasIPaganaGTerzoudiSEvangelouGLifetime prevalence fluctuations of chronic plaque psoriasis and other non-pustular clinical variantsJ Eur Acad Dermatol Venereol200822121513151418482310
   PubMed Web of Science ®Google Scholar
• RahoGKolevaDMGarattiniLNaldiLThe burden of moderate to severe psoriasis: an overviewPharmacoeconomics201230111005101322994598
   PubMed Web of Science ®Google Scholar
• JacobsPBissonnetteRGuentherLCSocioeconomic burden of immune-mediated inflammatory diseases – focusing on work productivity and disabilityJ Rheumatol Suppl201188556122045980
   PubMedGoogle Scholar
• Lewis-BeckCAbouzaidSXieLBaserOKimEAnalysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modelingPatient Prefer Adherence2013719920523508007
   PubMed Web of Science ®Google Scholar
• KimballABGuérinATsanevaMEconomic burden of comorbidities in patients with psoriasis is substantialJ Eur Acad Dermatol Venereol201125215716320561129
   PubMed Web of Science ®Google Scholar
• International Federation of Psoriasis AssociationPsoriasis is a serious disease deserving global attention [webpage on the Internet] Available at: http://www.ifpa-pso.org/getfile.ashx?cid=279366&cc=3&refid=18Accessed November 13, 2014
   Google Scholar
• LiuYWuEQBensimonAGCost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritisAdv Ther201229762063422843208
   PubMed Web of Science ®Google Scholar
• PathiranaDOrmerodADSaiagPEuropean S3-guidelines on the systemic treatment of psoriasis vulgarisJ Eur Acad Dermatol Venereol200923Suppl 217019712190
   PubMed Web of Science ®Google Scholar
• GiannettiACommentary on the European S3-guidelines on the systemic treatment of psoriasisJ Eur Acad Dermatol Venereol2010243368 author reply 368–36920070453
   PubMed Web of Science ®Google Scholar
• PathiranaDNastAOrmerodADOn the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challengesJ Eur Acad Dermatol Venereol201024121458146720456548
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology2008Guidelines of care for the management of psoriasis and psoriatic arthritis Available at: https://www.aad.org/File%20Library/Global%20navigation/Education%20and%20quality%20care/Guidelines-psoriasis-sec-2.pdfAccessed October 15, 2014
   Google Scholar
• HsuSPappKALebwohlMGNational Psoriasis Foundation Medical BoardConsensus guidelines for the management of plaque psoriasisArch Dermatol201214819510222250239
   PubMedGoogle Scholar
• ReichKBurdenADEatonJNHawkinsNSEfficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBr J Dermatol2012166117918821910698
   PubMed Web of Science ®Google Scholar
• Galván-BanqueriMMarín GilRSantos RamosBBautista PalomaFJBiological treatments for moderate-to-severe psoriasis: indirect comparisonJ Clin Pharm Ther201338212113023442134
   PubMed Web of Science ®Google Scholar
• KimIHWestCEKwatraSGFeldmanSRO’NeillJLComparative efficacy of biologics in psoriasis: a reviewAm J Clin Dermatol201213636537422967166
   PubMed Web of Science ®Google Scholar
• WeinbergJMAn overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisClin Ther200325102487250514667953
   PubMed Web of Science ®Google Scholar
• TutroneWDSainiRWeinbergJMBiological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefaceptIDrugs200471454914730466
   PubMed Web of Science ®Google Scholar
• SainiRTutroneWDWeinbergJMAdvances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusCurr Pharm Des200511227328015638763
   PubMed Web of Science ®Google Scholar
• WeinbergJMBottinoCJLindholmJBuchholzRBiologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefaceptJ Drugs Dermatol20054554455516167412
   PubMedGoogle Scholar
• RavalKLoflandJHWatersHPiechCTDisease and treatment burden of psoriasis: examining the impact of biologicsJ Drugs Dermatol201110218919621283925
   PubMed Web of Science ®Google Scholar
• LangleyRGEffective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?J Eur Acad Dermatol Venereol201226Suppl 2212922356632
   PubMed Web of Science ®Google Scholar
• SivamaniRKGoodarziHGarciaMSBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoringClin Rev Allergy Immunol201344212114022311162
   PubMed Web of Science ®Google Scholar
• BakerELColemanCIReinhartKMEffect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-AnalysesDermatol Ther (Heidelb)201221923205332
   PubMedGoogle Scholar
• KentikelenisAKaranikolosMPapanicolasIBasuSMcKeeMStucklerDHealth effects of financial crisis: omens of a Greek tragedyLancet201137898011457145821988763
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEPAR summary for the public: Humira (adalimumab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000481/WC500050865.pdfAccessed November 13, 2014
   Google Scholar
• European Medicines AgencyEPAR summary for the public: Enbrel (etanercept) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000262/WC500027364.pdfAccessed November 13, 2014
   Google Scholar
• European Medicines AgencyEPAR summary for the public: Remicade (infliximab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000240/WC500050883.pdfAccessed November 13, 2014
   Google Scholar
• European Medicines AgencyEPAR summary for the public: Stelara (ustekinumab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000958/WC500058509.pdfAccessed November 13, 2014
   Google Scholar
• Ministry of Health, price bulletin 81505/30-08-2013, YA Available at: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/1860-diorthwtiko-deltio-timwn-30-08-2013Accessed August 10, 2013 Greek
   Google Scholar
• MauskopfJASullivanSDAnnemansLPrinciples of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysisValue Health200710533634717888098
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet200336193641197120412686053
   PubMed Web of Science ®Google Scholar
• SchonMPBoehnckeWHPsoriasisNEJM2005352181899191215872205
   PubMed Web of Science ®Google Scholar
• NijstenTMargolisDJFeldmanSRRolstadTSternRSTraditional systemic treatments have not fully met the needs of psoriasis patients: results from a national surveyJ Am Acad Dermatol2005523 Pt 143444415761421
   PubMed Web of Science ®Google Scholar
• ArmstrongAWHarskampCTArmstrongEJThe association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutr Diabetes20122e5423208415
   PubMed Web of Science ®Google Scholar
• NastABoehnckeWHMrowietzUDeutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD)S3 – Guidelines on the treatment of psoriasis vulgaris (English version). UpdateJ Dtsch Dermatol Ges201210Suppl 2S1S95
   Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJN(Chair of Guideline Group)British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009Br J Dermatol20091615987101919857207
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
   PubMed Web of Science ®Google Scholar
• BrezinskiEAArmstrongAWOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPLoS One201274e3348622509259
   PubMed Web of Science ®Google Scholar
• VillacortaRHayJWMessaliACost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United StatesPharmacoeconomics201331982383923975739
   PubMed Web of Science ®Google Scholar
• AhnCSGustafsonCJSandovalLFDavisSAFeldmanSRCost effectiveness of biologic therapies for plaque psoriasisAm J Clin Dermatol201314431532623696234
   PubMed Web of Science ®Google Scholar
• NelsonAAPearceDJFleischerABJrBalkrishnanRFeldmanSRCost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJ Am Acad Dermatol200858112513517996329
   PubMed Web of Science ®Google Scholar
• FerrándizCGarcíaABlascoAJLázaroPCost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasisJ Eur Acad Dermatol Venereol201226676877722126264
   PubMed Web of Science ®Google Scholar
• SamarasekeraESawyerLParnhamJSmithCHGuideline Development G. Assessment and management of psoriasis: summary of NICE guidanceBMJ2012345e671223097521
   PubMed Web of Science ®Google Scholar
• DrummondMBarbieriMCookJTransferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportValue Health200912440941819900249
   PubMed Web of Science ®Google Scholar
• IannazzoSDe FrancescoMGomez-UlloaDBenucciMA review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritisExpert Rev Pharmacoecon Outcomes Res201313445546823977974
   PubMed Web of Science ®Google Scholar
• Salmon-CeronDTubachFLortholaryORATIO groupDrug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registryAnn Rheum Dis201170461662321177290
   PubMed Web of Science ®Google Scholar
• TubachFSalmonDRavaudPResearch Axed on Tolerance of Biotherapies GroupRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum20096071884189419565495
   PubMed Web of Science ®Google Scholar
• MarietteXTubachFBagheriHLymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registryAnn Rheum Dis201069240040819828563
   PubMed Web of Science ®Google Scholar
• PiasericoSContiALo ConsoleFEfficacy and safety of systemic treatments for psoriasis in elderly patientsActa Derm Venereol201494329329724158307
   PubMed Web of Science ®Google Scholar
• TohSLiLHarroldLRComparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Pharmacoepidemiol Drug Saf201221552453422411435
   PubMed Web of Science ®Google Scholar
• PearceDJHigginsKBStealeyKHAdverse events from systemic therapies for psoriasis are common in clinical practiceJ Dermatolog Treat200617528829317092859
   PubMed Web of Science ®Google Scholar
• SiztoSBansbackNFeldmanSRWillianMKAnisAHEconomic evaluation of systemic therapies for moderate to severe psoriasisBr J Dermatol200916061264127219120346
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellencePsoriasis: The assessment and management of psoriasis Available at: https://www.nice.org.uk/guidance/cg153/resources/guidance-psoriasis-pdfAccessed October 15, 2014
   Google Scholar
• FragoulakisVKourlabaGGoumenosDKonstantoulakisMManiadakisNEconomic evaluation of intravenous iron treatments in the management of anemia patients in GreeceClinicoecon Outcomes Res2012412713422629113
   PubMedGoogle Scholar
• AvgerinouGBassukasIChaidemenosGBudget impact analysis of ustekinumab in the management of moderate to severe psoriasis in GreeceBMC Dermatol2012121022831458
   PubMedGoogle Scholar